GLP-1/GIP dual agonist

Tirzepatide — Research Reference Guide

Tirzepatide is a dual incretin research compound that engages both GLP-1 and GIP receptors. This reference covers what laboratory teams typically verify before adding it to a study.

Dual incretin mechanism

Tirzepatide combines GLP-1 and GIP receptor activity in a single sequence. The dual agonism is the primary reason it has attracted intense metabolic-research interest over the past several years.

Reconstitution & cold chain

Standard practice mirrors other long-acting GLP-1 research peptides: lyophilised storage at 2–8°C, reconstitution with bacteriostatic water and refrigerated in-use stability of around four weeks.

Purity and batch data

Each Regena batch publishes an HPLC purity figure and identity confirmation by mass spectrometry. Always cross-check the COA before any quantitative work.

Where it fits in the catalogue

Tirzepatide is available across multiple strengths in the Peptide Library so laboratories can right-size kits to study duration without wasted reconstituted material.

Frequently asked questions

Is tirzepatide the same as semaglutide?+

No — semaglutide is a GLP-1 mono-agonist; tirzepatide engages both GLP-1 and GIP receptors and has a distinct sequence and pharmacology.

Does the kit include bacteriostatic water?+

Bacteriostatic water is sold separately in the Peptide Library. Most teams order one bottle per kit.

Can I see prior batch COAs?+

Yes — historical COAs are archived on the lab reports page.

Continue your research

Trusted reference supplier · Verified across review platforms